Lyell Immunopharma (LYEL) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

LYEL Lyell Immunopharma

Watchlist

0.913
-0.037-3.91%

Close Nov 25 16:00 ET

0.920
+0.007+0.78%

Post 20:01 ET

254.90MMarket Cap-1155P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

The Analyst Verdict: Lyell Immunopharma In The Eyes Of 4 Experts
BenzingaNov 12 07:00 ET
Express News | HC Wainwright & Co. Reiterates Neutral on Lyell Immunopharma, Maintains $1 Price Target
BenzingaNov 12 06:45 ET
Lyell Immunopharma Analyst Ratings
BenzingaNov 12 06:40 ET · Ratings
Mitchell Kapoor Maintains Hold Rating on Lyell Immunopharma Amid Promising IMPT-314 Results and Market Challenges
TipRanksNov 12 06:16 ET · Ratings
Positive Week for Lyell Immunopharma, Inc. (NASDAQ:LYEL) Institutional Investors Who Lost 26% Over the Past Year
Simply Wall StNov 10 08:09 ET
Lyell Immunopharma Reports Q3 Net Loss $44.6M Vs. $50.9M Last Year
TipRanksNov 7 17:16 ET

Comments

71875619

Nov 20 14:11

$Lyell Immunopharma (LYEL.US)$ what a day

Teddy123

Nov 8 05:40

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024

$Lyell Immunopharma (LYEL.US)$
Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate with strong Phase 1 clinical data in patients with aggressive relapsed/refractory B-cell non-Hodgkin’s lymphoma
Presenting initial data from Phase 1 multi-center clinical trial of IMPT-314 at the American Society of Hematology 2024...

Teddy123

Nov 7 07:15

When will u start moving

$Lyell Immunopharma (LYEL.US)$

Teddy123

Nov 5 08:39

Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting

$Lyell Immunopharma (LYEL.US)$
05/11/2024 - 22:30
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors or hematologic malignancies, ...